{"entity":{"type":"insider","cik":"0001914523","url":"/insider/0001914523","json_url":"/insider/0001914523.json","name":"Ogden Christopher","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":9,"n_filings":8,"first":"2023-03-20","last":"2026-06-17","span_basis":"filed_date"},"name_variants":[{"name":"Ogden Christopher","source":"filing","n_filings":8,"first_seen":"2023-03-20","last_seen":"2026-06-17"}],"transactions":[{"id":5845425,"accession":"0001610717-26-000229","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001610717-26-000229","line_url":"/filing/0001610717-26-000229#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001914523","owner_name":"Ogden Christopher","owner_display_name":"Ogden Christopher","owner_url":"/insider/0001914523","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1624.0,"shares_display":"1,624","price_per_share":3.05,"price_display":"3.05","price_state":"stated","total_value":4953.2,"total_display":"4,953.20","total_whole":"4,953","shares_owned_after":295324.0,"shares_owned_after_display":"295,324","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-15","filed_date":"2026-06-17","scope":"insider"},{"id":5982151,"accession":"0001610717-26-000122","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001610717-26-000122","line_url":"/filing/0001610717-26-000122#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001914523","owner_name":"Ogden Christopher","owner_display_name":"Ogden Christopher","owner_url":"/insider/0001914523","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19323.0,"shares_display":"19,323","price_per_share":6.423,"price_display":"6.42","price_state":"stated","total_value":124111.629,"total_display":"124,111.63","total_whole":"124,112","shares_owned_after":296948.0,"shares_owned_after_display":"296,948","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-17","filed_date":"2026-03-19","scope":"insider"},{"id":4334050,"accession":"0001610717-25-000236","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001610717-25-000236","line_url":"/filing/0001610717-25-000236#line-3","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001914523","owner_name":"Ogden Christopher","owner_display_name":"Ogden Christopher","owner_url":"/insider/0001914523","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10614.0,"shares_display":"10,614","price_per_share":2.6889,"price_display":"2.69","price_state":"stated","total_value":28539.9846,"total_display":"28,539.98","total_whole":"28,540","shares_owned_after":226271.0,"shares_owned_after_display":"226,271","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-16","filed_date":"2025-06-17","scope":"insider"},{"id":4334046,"accession":"0001610717-25-000236","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001610717-25-000236","line_url":"/filing/0001610717-25-000236#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001914523","owner_name":"Ogden Christopher","owner_display_name":"Ogden Christopher","owner_url":"/insider/0001914523","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1641.0,"shares_display":"1,641","price_per_share":2.9503,"price_display":"2.95","price_state":"stated","total_value":4841.4423,"total_display":"4,841.44","total_whole":"4,841","shares_owned_after":199385.0,"shares_owned_after_display":"199,385","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-13","filed_date":"2025-06-17","scope":"insider"},{"id":4675378,"accession":"0001610717-25-000085","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001610717-25-000085","line_url":"/filing/0001610717-25-000085#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001914523","owner_name":"Ogden Christopher","owner_display_name":"Ogden Christopher","owner_url":"/insider/0001914523","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8551.0,"shares_display":"8,551","price_per_share":0.599,"price_display":"0.60","price_state":"stated","total_value":5122.049,"total_display":"5,122.05","total_whole":"5,122","shares_owned_after":201026.0,"shares_owned_after_display":"201,026","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-18","filed_date":"2025-03-20","scope":"insider"},{"id":2429412,"accession":"0001610717-24-000433","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001610717-24-000433","line_url":"/filing/0001610717-24-000433#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001914523","owner_name":"Ogden Christopher","owner_display_name":"Ogden Christopher","owner_url":"/insider/0001914523","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1984.0,"shares_display":"1,984","price_per_share":1.2291,"price_display":"1.23","price_state":"stated","total_value":2438.5344,"total_display":"2,438.53","total_whole":"2,439","shares_owned_after":108077.0,"shares_owned_after_display":"108,077","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-20","filed_date":"2024-08-22","scope":"insider"},{"id":2969039,"accession":"0001610717-24-000177","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001610717-24-000177","line_url":"/filing/0001610717-24-000177#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001914523","owner_name":"Ogden Christopher","owner_display_name":"Ogden Christopher","owner_url":"/insider/0001914523","role":"Officer (SVP, Finance and Accounting)","role_mark":"O","role_mark_label":"Officer (SVP, Finance and Accounting)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Finance and Accounting","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2971.0,"shares_display":"2,971","price_per_share":2.0855,"price_display":"2.09","price_state":"stated","total_value":6196.0205,"total_display":"6,196.02","total_whole":"6,196","shares_owned_after":85686.0,"shares_owned_after_display":"85,686","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-19","filed_date":"2024-03-21","scope":"insider"},{"id":8451579,"accession":"0001610717-23-000419","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001610717-23-000419","line_url":"/filing/0001610717-23-000419#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001914523","owner_name":"Ogden Christopher","owner_display_name":"Ogden Christopher","owner_url":"/insider/0001914523","role":"Officer (SVP, Finance and Accounting)","role_mark":"O","role_mark_label":"Officer (SVP, Finance and Accounting)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Finance and Accounting","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1990.0,"shares_display":"1,990","price_per_share":1.3806,"price_display":"1.38","price_state":"stated","total_value":2747.394,"total_display":"2,747.39","total_whole":"2,747","shares_owned_after":48657.0,"shares_owned_after_display":"48,657","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-20","filed_date":"2023-12-22","scope":"insider"},{"id":8413970,"accession":"0001140361-23-012619","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-23-012619","line_url":"/filing/0001140361-23-012619#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001914523","owner_name":"Ogden Christopher","owner_display_name":"Ogden Christopher","owner_url":"/insider/0001914523","role":"Officer (SVP, Finance and Accounting)","role_mark":"O","role_mark_label":"Officer (SVP, Finance and Accounting)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Finance and Accounting","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":516.0,"shares_display":"516","price_per_share":1.9793,"price_display":"1.98","price_state":"stated","total_value":1021.3188,"total_display":"1,021.32","total_whole":"1,021","shares_owned_after":37772.0,"shares_owned_after_display":"37,772","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-16","filed_date":"2023-03-20","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":9,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":9,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":9},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001501989","name":"CytomX Therapeutics, Inc.","url":"/issuer/0001501989","role":"Officer (Chief Financial Officer)","n_filings":8,"first_seen":"2023-03-20","last_seen":"2026-06-17"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001914523","retrieved_at":"2026-08-25T04:22:37+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}